AlphaMadera's AlphaVal page classifies Elevance Health Inc. as a Stable Earnings Power business and values it using P/Adj-EPS × Normalized Multiple, then compares the result to the current market price to flag ELV as undervalued, fairly valued, or overvalued.

What is Elevance Health Inc.'s fair value?

Fair value for ELV comes from a P/Adj-EPS × Normalized Multiple model -- the approach AlphaVal selected for this company's Stable Earnings Power classification. The live AlphaVal page shows bear, base, and bull scenarios alongside the key assumption behind each.

How does AlphaMadera value ELV?

AlphaVal routes each company to one of ten valuation archetypes based on its business model. ELV was classified as Stable Earnings Power and is valued using P/Adj-EPS × Normalized Multiple, built from ELV's most recent reported fundamentals.

ELV - Elevance Health Inc.

Price: -- -- | CONSENSUS: Buy DETAILS | PRICE TARGET: $444.06 DETAILS

AlphaVal

Deterministic, archetype-aware fair value

Stable Earnings Power 80% confidence

Primary model: P/Adj-EPS × Normalized Multiple

Valuation Signal Overvalued Moderate

Trading 25.6% above fair value

Current Price $394.43

Bear Case $251.20 36.3% downside ($251.20 - $394.43) / $394.43 = -36.3% $25.12 × 10x P/E

Fair Value $314.00 20.4% downside ($314.00 - $394.43) / $394.43 = -20.4% $25.12 × 12x P/E

Bull Case $376.80 4.5% downside ($376.80 - $394.43) / $394.43 = -4.5% $25.12 × 15x P/E

Adjust Assumptions

P/E Multiple

12.5x

Adjusted EPS

25.12$

Key Value Driver

Normalized P/E multiple (12x base case)

Terminal Value % of EV

Implied Market Multiple 15.7x

Market is pricing in (growth)

Plain-Language Summary

Applying a 12x P/E to adjusted EPS of $25.12, the base-case value is $314.00 per share. DDM cross-check: $559.12.

Analyst Consensus (External Reference)

Never blended into the bear/base/bull estimates above -- shown only as an outside comparison.

Average Target (38 analysts) $444.06

Analyst Range $391.00 – $498.00

Divergence from AlphaVal 29%

Warnings

ℹ Dividend-based valuation: $559.12 (above our primary estimate by 78%). Large gaps may signal the dividend doesn't reflect full earning power.

ℹ Wall Street's average price target is $444.06 (from 38 analysts). Our estimate is 29% below the consensus -- consider that gap carefully.

Key Risks

Growth DCF inappropriate — terminal value assumptions dominate
EV/EBITDA misleading for regulated businesses where capex is mandated
Regulatory risk is a fat tail not visible in normal multiples